B01 NOI Illumina.doc
DOC document 29 KB Posted
- Solicitation number
- PANDHA25P0000028745NOI
- Issued by
- Not on record
About this file
This document is a Notice of Intent (NOI) from the United States Army Medical Research Acquisition Activity (USAMRAA) to issue a sole source award to Bio-Active Co., Ltd on behalf of the Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute Medical Sciences (AFRIMS). The procurement is for commercial laboratory and medical supplies in Thailand, specifically Illumina sequencing platform-compatible reagents and supplies essential for high-throughput sequencing workflows involving microbial surveillance, viral detection, influenza typing, and gene expression profiling.
The NOI requires potential sources to respond in writing within 15 days of publication, providing clear evidence of their capability to provide comparable services. If no substantive responses are received demonstrating more advantageous alternatives, USAMRAA will proceed with the sole source acquisition. Interested parties must submit their responses to john.l.fitzsimmons8.civ@health.mil, with documentation that goes beyond a mere request for documentation. The solicitation number is PANDHA25P0000028745NOI, and the opportunity is classified as a Special Notice focused on brand name Illumina reagents, kits, and consumables under a Blanket Purchase Agreement (BPA).
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
The United States Army Medical Research Acquisition Activity (USAMRAA), Fort Detrick, MD intends to issue a sole source award to Bio-Active Co., Ltd on behalf of the Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute Medical Sciences (AFRIMS). For commercial laboratory and medical supplies in Thailand. The required medical supplies and reagent are essential to support high-throughput sequencing workflows used for microbial surveillance, viral detection, influenza typing, and gene expression profiling. The specific products listed are critical due to their validated compatibility with Illumina sequencing platforms (MiSeq, NextSeq 1000/2000), standardized protocols, and integrated quality control elements, which ensure data accuracy, reproducibility, and compliance with laboratory standard operating procedures (SOPs).
This notice of intent is for award for informational purposes only. All sources eligible to provide this service must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide services outlined above. A request for documentation will not be considered as an affirmative response. If no responses are received, within 15 days after publication of this notice, to the effect that comparable services are available, and that it is more advantageous to the Government than obtaining these services through a sole-source contract, then a sole source acquisition award will be made. Response to this notice is to be sent to john.l.fitzsimmons8.civ@health.mil
File details come from the government source that posted it. Updated .